Mr. Diver has been in the pharmaceutical industry for over 30 years, having served technical and commercial leadership roles for both innovator companies and CDMOs. Currently, he is the Director of Commercial Development in the Lonza Pharma Biotech & Nutrition Segment at Lonza focused on late stage, small molecule Drug Substances. Mr. Diver has been an active member of DCAT for many years participating on various committees, serving as chair of the DCAT Technology Committee, as a member of the Advisory Council, and as a member of the Board of Directors. Mr. Diver holds a B.S. in chemical engineering from Lehigh University.
SECOND VICE PRESIDENT
Kerri McCullough Wood
Kerri McCullough Wood is currently Senior Vice President and Head of Commercial Teva api and Medis, both global, B2B businesses within Teva Pharmaceuticals, driving profitable and sustainable growth for the organization. Ms. Wood is an accomplished senior executive in the pharmaceutical industry, with over 20 years’ experience, currently managing a P&L in excess of $1 billion. Ms. Wood has a proven track record of developing and implementing the commercial strategy, driving organizational transformation, and leading through uncertainty, while continuing to keep a strong focus on customer centricity and building strong relationships.
Ms. Wood earned an MBA from Fairleigh Dickinson University and holds a B.S. in biology, with a health sciences minor and a pre-medical focus from Boston College. Previously, she served as the chair of DCAT’s Education Committee and on DCAT’s board as a director.
THIRD VICE PRESIDENT
Sally Macaluso is the Vice-President and Chief Procurement Officer of Johnson & Johnson Medical Devices and Business Services Procurement. In this role, Sally is responsible for the business engagement activities for the Johnson & Johnson Medical Devices sector. Sally is also responsible for managing $8.5 billion of global Enterprise-wide spend in the Business Services categories which include Travel, Fleet, and Meetings; HR Services; Corporate Services; Professional Education and Access; and IT. Sally is a member of the Johnson & Johnson Procurement Leadership Team.
Prior to this role, Sally was the Vice President of Marketing and Business Services Procurement where she managed $13 billion in spend across the two category families. Sally joined the company as the Vice-President of Johnson & Johnson R&D Procurement, a position that she served in for four years.
Sally is very passionate about women’s leadership. She was the Executive Sponsor of the Procurement Women’s Leadership Initiative for five years. She also currently serves as the Executive Sponsor for the Professional Pillar of the enterprise Women in Science, Technology, Engineering, Math, Manufacturing, & Design (WiSTEM2D) Program.
Before joining Johnson & Johnson in 2012, Sally spent 18 years at Merck & Co, Inc. where she worked in the Merck Research Laboratories and then held various leadership positions in Global Procurement supporting many different indirect and direct categories. Sally has a Bachelor’s degree in chemistry from Bucknell University and a Master’s degree in chemistry from Lehigh University.
Elodie Cramer is an experienced purchasing professional with over 24 years of experience in both direct and indirect categories, inclusive of contract manufacturing, packaging, distribution and logistics, and corporate services in the biopharmaceutical, flavor & fragrance and aluminum industries. She is currently associate director of global sourcing at Biogen where she is responsible for sourcing strategy development and implementation for large molecule drug substance and small molecule API as well Gene Therapy drug substance and drug product contract manufacturing categories.
Prior to joining Biogen, she was director of global strategic purchasing, professional services at Constellium. From 1994-2008 she held various positions at Bristol-Myers Squibb, rising to associate director of new product launch, technical operations where she formed and led multi-functional teams for all aspects of the manufacturing launch plan in diabetes, oncology, and cardiovascular therapeutic areas.
Ms. Cramer recently served on DCAT’s Advisory Council. She holds a B.A. and a specialized master in purchasing management from KEDGE Business School and the Institut du Management de l’Achat International (M.A.I) in Bordeaux, France.
Lori A. Hoffman is the Head of Alliance Management for Slayback Pharma. She has 30 years of broad pharmaceutical industry experience in API & Finished Dosage R&D and manufacturing, project and alliance management, licensing, product selection, and business development. Ms. Hoffman has been an active DCAT volunteer for the past eight years, as a member of the Education Committee, the Advisory Council, and most recently as the Chair of the Alliance for Industry Women Committee. Ms. Hoffman earned a B.S. in chemistry from the University of Wisconsin-Madison and has completed additional coursework in economics, accounting, and communication.
Mr. Davies is a pharmaceuticals procurement and operations executive with over 20 years of experience in organizational design, strategy development and implementation across direct and indirect categories. He is currently associate vice president, global sourcing and procurement for Merck’s Global Pharmaceutical Operations where he leads the development and execution of procurement strategies supporting Merck’s small molecule business and is part of the Global Pharmaceutical Operations (GPO) Leadership Team accountable for sourcing and procurement activities across three regions, supporting 16 manufacturing sites and more than 115 CMOs. Prior to joining Merck, he was vice president, global procurement at Teva Pharmaceuticals where he designed, recruited and staffed Global Procurement for Third Party Operations and the Americas region. From 2004-2014 he held various positions at Pfizer and Wyeth (prior to its acquisition by Pfizer), leading global strategic sourcing and API planning teams across EMEA, Americas, and APAC.
Mr. Davies recently served on DCAT’s Advisory Council and was a board member of the Philadelphia Drug Exchange, Pharmaceutical Trade Organization. He holds a B.S. in business logistics from Pennsylvania State University, University Park, PA.
Gavin Murdoch has been in the pharmaceutical industry for over 32 years, having served in operational, technical, procurement and business development leadership roles for both Merck and Co Inc and ThermoFisher. Currently, as Senior Director for Strategic Partnerships, he leads teams that create novel technology and supply chain solutions to serve customer’s innovation and growth needs across drug substance, biologic and API. Mr. Murdoch has been an active member of DCAT for many years participating on various committees, serving as chair of the DCAT Education Committee, and as a member of the Board of Directors. Mr. Murdoch holds a B.S. in chemical engineering from the University of Connecticut, MBA in finance from Villanova University, and Masters in Engineering Management from Wharton and the University of Pennsylvania.
Mr. Poland has been in the pharmaceuticals industry for 25 years, having spent the past 21 years with Viatris (formerly Mylan N.V.). He has held various roles throughout his career, starting as a chemist in the Quality Control Laboratory, followed by leadership roles within Quality Assurance (Manufacturing and Packaging). For the past 15 years, he has been a part of the Procurement team, leading and expanding Mylan’s Innovative Purchasing Technical Services team to a global scale. Currently, he is the director of 3rd party finished dose form sourcing. He is responsible for the relationship management and technical oversight of Mylan’s 3rd party CMO’s in North America.
Mr. Poland has been attending DCAT events since 2004 and has been an active participant in the DCAT organization for the past 3 years, serving on the Advisory Council and the Leadership Development Committee.
He holds a bachelor’s degree in chemistry and an M.S. in industrial and labor relations from West Virginia University.
Scott is a career sales executive with over 22 years of pharmaceutical industry experience. Scott has proudly been with Ren-Pharm international for 16 years and is currently the Vice President of Sales. Ren-Pharm International is an industry leading and globally recognized agent specializing in active pharmaceutical ingredients and the drug development process from R&D through commercialization. Ren-Pharm International represents several industry leading API suppliers, and during Scott’s tenure Ren-Pharm International has been instrumental in identifying API’s and executing strategy to support some of the most highly recognized and highest value ANDA product approvals and first-to-file launches.
Prior to joining Ren-Pharm International, Scott worked for six years with Ortho-McNeil Pharmaceuticals, a Johnson & Johnson Company, holding sales positions of increasing responsibility. Scott graduated from Stetson University with a BS in Business Marketing.
Scott has been an active DCAT volunteer for the past six years as a member of the Science and Scholarship Committee, serving the last five years as the committee chair. Scott was instrumental in developing and participating in DCAT’s primary scholarship initiative as a Special Awards Sponsor for the International Science and Engineering Fair, which provides cash awards to talented and deserving young scientists and future industry leaders.
IMMEDIATE PAST PRESIDENT
Paolo Magrì is CEO of the Bioseutica Group, active in the production of pharma grade natural proteins and enzymes. The Group is headquartered in The Netherlands, with offices in Switzerland and production sites in British Columbia (CA). Mr. Magrì has over 30 years of experience in the active pharmaceutical ingredient (API) industry. Prior to joining Bioseutica, he served as senior VP at Advitech Advisory and Technologies. Previous to that role, he served as Vice President of corporate business development at Infa Group, and as marketing and sales Director at Sicor and in Teva’s API division, after the acquisition of Sicor by Teva in 2004.
His strong track record in the industry also includes previous roles at Archimica/Pro.Bio.Sint. and Fordras. Mr. Magrì earned his Master’s degree in chemistry and pharmaceutical technology from the University of Milan, Italy.
SECOND IMMEDIATE PAST PRESIDENT
Mr. Sutton is the global director of global sourcing for Lilly’s development and manufacturing organizations. He has over 30 years of experience with Eli Lilly and Company, having held various roles in support of the manufacturing organization including IT, supply chain operations, finance and procurement. He is currently responsible for developing and implementing the global sourcing strategies for API, MRO and Analytical Services across the development and manufacturing pipeline. In prior roles he has managed the sourcing strategy for facilities management and utilities, as well as health, wellness and benefit programs, recruiting services and learning and development services.
Mr. Sutton has been an active DCAT event participant since 2000 and joined DCAT’s Supply Chain Management Committee in 2011. He was appointed chairperson of the Supply Management Committee for 2013-2014 and served on the Advisory Council of the Board of Directors from 2010-2013. He is Immediate Past President of DCAT, having served from 2017 to 2018.
He holds a B.S. in management information systems from Brigham Young University and an M.B.A. from Indiana State University.
Ms. Timony currently serves as the executive director of the Drug, Chemical & Associated Technologies Association (DCAT). Ms. Timony joined DCAT in December of 1998 after the organization moved its headquarters from New York to New Jersey. During her tenure, she has been responsible for overseeing the strategic direction and operations for the global business development association with 100+ active volunteers and a staff of 10.
Prior to this, Ms. Timony was the executive director of the American Physical Therapy Association of New Jersey (APTAnj) where she was responsible for the management and operations of the 2,500 member professional society which included legislative and regulatory advocacy. During her tenure at APTAnj, she also served concurrently as the executive director of the Acute Care practice section and the Research section for the national APTA organization.
A graduate of Widener University, she is active in association management professional societies and served as a board member and past president of the Middle Atlantic Society of Association Executives. She is also a member of the American Society of Association Executives and has led several small-staffed association group forums and committees.
DCAT is a not-for-profit business development association committed to providing learning experiences and industry activities that enhance knowledge and create opportunities for members to expand their network of customers and suppliers throughout the global Bio/Pharmaceutical manufacturing value chain.
Drug, Chemical & Associated Technologies Association (DCAT)
GLOBAL HEADQUARTERS One Union St., Suite 207 Robbinsville, NJ, 08691, USA